Factors associated with RFS in 49 patients with mastocytosis treated by 2-CdA
Covariates . | HR . | 95% CI . | P . |
---|---|---|---|
Male gender | 0.69 | 0.34-1.42 | .31 |
AHNMD vs ISM/SSM/CM/MIS | 0.66 | 0.25-1.73 | .40 |
ASM vs ISM/SSM/CM/MIS | 1.20 | 0.46-3.18 | .71 |
Age at mastocytosis diagnosis >50 y | 1.25 | 0.62-2.52 | .53 |
Age at 2-CdA initiation >55 y | 0.73 | 0.36-1.49 | .39 |
Fatigue | 0.84 | 0.38-1.86 | .66 |
Flush | 1.22 | 0.61-2.46 | .58 |
Pruritus | 1.61 | 0.79-3.29 | .19 |
Abdominal pain | 1.82 | 0.91-3.63 | .09 |
Diarrhea | 1.39 | 0.69-2.81 | .36 |
Hepatosplenomegaly | 1.06 | 0.53-2.09 | .88 |
Urticaria pigmentosa | 1.42 | 0.70-0.55 | .46 |
Bone involvement (yes vs no) | 0.50 | 0.24-1.04 | .06 |
Anemia <10g/dL | 1.18 | 0.49-2.88 | .71 |
>3 courses of 2-CdA | 1.72 | 0.84-3.49 | .14 |
>4 courses of 2-CdA | 2.79 | 1.30-6.02 | .009 |
Partial response | 2.16 | 1.05-4.44 | .037 |
Covariates . | HR . | 95% CI . | P . |
---|---|---|---|
Male gender | 0.69 | 0.34-1.42 | .31 |
AHNMD vs ISM/SSM/CM/MIS | 0.66 | 0.25-1.73 | .40 |
ASM vs ISM/SSM/CM/MIS | 1.20 | 0.46-3.18 | .71 |
Age at mastocytosis diagnosis >50 y | 1.25 | 0.62-2.52 | .53 |
Age at 2-CdA initiation >55 y | 0.73 | 0.36-1.49 | .39 |
Fatigue | 0.84 | 0.38-1.86 | .66 |
Flush | 1.22 | 0.61-2.46 | .58 |
Pruritus | 1.61 | 0.79-3.29 | .19 |
Abdominal pain | 1.82 | 0.91-3.63 | .09 |
Diarrhea | 1.39 | 0.69-2.81 | .36 |
Hepatosplenomegaly | 1.06 | 0.53-2.09 | .88 |
Urticaria pigmentosa | 1.42 | 0.70-0.55 | .46 |
Bone involvement (yes vs no) | 0.50 | 0.24-1.04 | .06 |
Anemia <10g/dL | 1.18 | 0.49-2.88 | .71 |
>3 courses of 2-CdA | 1.72 | 0.84-3.49 | .14 |
>4 courses of 2-CdA | 2.79 | 1.30-6.02 | .009 |
Partial response | 2.16 | 1.05-4.44 | .037 |
AHNMD, associated hematologic non–mast cell disease; ASM, aggressive systemic mastocytosis; CM, cutaneous mastocytosis; ISM, indolent systemic mastocytosis; MIS, mastocytosis in the skin; SSM, smoldering systemic mastocytosis
Bold indicates significant parameters in univariate analysis.